GLP-1s are a big cost problem. Do they have to be?

David Williams is quoted in the Boston Globe (What Trump’s GLP=1 deal means for the many Massachusetts residents who use weight-loss drugs)

David E. Williams, president of the Boston consulting firm Health Business Group, welcomed the move by the Trump administration to lower the cost of GLP-1s.

“Employers and insurers are dropping coverage, and now there’s a lifeboat from the White House,” he said.

The point is that GLP-1s should actually be very cost effective. But prices may need to be lower and they need to be incorporated into a more holistic health program.